Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model.

MLA

Van Campenhout, Sanne, et al. “Myeloid-Specific IRE1alpha Deletion Reduces Tumour Development in a Diabetic, Non-Alcoholic Steatohepatitis-Induced Hepatocellular Carcinoma Mouse Model.” Metabolism: Clinical and Experimental, vol. 107, June 2020, p. 154220. EBSCOhost, https://doi.org/10.1016/j.metabol.2020.154220.

APA

Van Campenhout, S., Tilleman, L., Lefere, S., Vandierendonck, A., Raevens, S., Verhelst, X., Geerts, A., Van Nieuwerburgh, F., Van Vlierberghe, H., & Devisscher, L. (2020). Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model. Metabolism: Clinical and Experimental, 107, 154220. https://doi.org/10.1016/j.metabol.2020.154220

Chicago

Van Campenhout, Sanne, Laurentijn Tilleman, Sander Lefere, Astrid Vandierendonck, Sarah Raevens, Xavier Verhelst, Anja Geerts, Filip Van Nieuwerburgh, Hans Van Vlierberghe, and Lindsey Devisscher. 2020. “Myeloid-Specific IRE1alpha Deletion Reduces Tumour Development in a Diabetic, Non-Alcoholic Steatohepatitis-Induced Hepatocellular Carcinoma Mouse Model.” Metabolism: Clinical and Experimental 107 (June): 154220. doi:10.1016/j.metabol.2020.154220.